Tami Pilot-Matias Selected Research

paritaprevir

3/2019	Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).
1/2019	Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
10/2018	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
1/2018	Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
1/2017	Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
1/2017	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
1/2017	Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
1/2016	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
11/2015	Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
10/2015	Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tami Pilot-Matias Research Topics

Disease

31	Infections 10/2019 - 06/2007
20	Fibrosis (Cirrhosis) 10/2019 - 01/2014
7	Chronic Hepatitis C 03/2019 - 07/2013
3	Hepatitis C 03/2019 - 01/2013
3	Virus Diseases (Viral Diseases) 01/2019 - 06/2015
2	Coinfection 01/2017 - 03/2015
2	Anemia 01/2017 - 12/2014
2	Body Weight (Weight, Body) 04/2014 - 01/2014
1	Liver Diseases (Liver Disease) 10/2019
1	Chronic Renal Insufficiency 10/2019
1	Nasopharyngitis 01/2017

Drug/Important Bio-Agent (IBA)

22	Ribavirin (Virazole)FDA LinkGeneric 10/2019 - 01/2013
21	paritaprevirIBA 03/2019 - 01/2013
20	ombitasvirIBA 03/2019 - 01/2014
19	Ritonavir (Norvir)FDA Link 03/2019 - 01/2013
16	InterferonsIBA 03/2019 - 01/2013
13	Antiviral Agents (Antivirals)IBA 10/2019 - 01/2013
9	dasabuvirIBA 01/2019 - 01/2013
7	glecaprevir and pibrentasvirIBA 10/2019 - 01/2018
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2016 - 01/2013
6	RNA (Ribonucleic Acid)IBA 01/2017 - 03/2015
5	SofosbuvirIBA 03/2019 - 01/2018
4	glecaprevirIBA 10/2019 - 01/2018
4	pibrentasvirIBA 10/2019 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 10/2019 - 01/2017
2	Atazanavir Sulfate (Reyataz)FDA Link 01/2017 - 03/2015
2	Raltegravir Potassium FDA Link 01/2017 - 03/2015
2	telaprevirIBA 04/2014 - 04/2014
1	ledipasvirIBA 01/2019
1	QuartzIBA 01/2019
1	Viekira PakIBA 10/2018
1	daclatasvirIBA 01/2018
1	Darunavir (Prezista)FDA Link 01/2017
1	dolutegravirIBA 01/2017
1	BilirubinIBA 01/2017
1	Hepatitis C AntibodiesIBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 11/2015
1	Pharmaceutical PreparationsIBA 10/2015
1	dimemorfan (AT 17)IBA 03/2015
1	Peptide Hydrolases (Proteases)FDA Link 02/2015
1	TabletsIBA 04/2014
1	PlacebosIBA 04/2014

Therapy/Procedure

9	Therapeutics 01/2019 - 06/2007
5	Duration of Therapy 03/2019 - 01/2017
2	Retreatment 01/2019 - 04/2014
1	Liver Transplantation 12/2014